Evidence map›Paper›PMID 40645641›Full record

ArticleBMJ open gastroenterology2025

Liver diseases, transaminases, and hepatobiliary-pancreatic cancer risk: a cohort and Mendelian randomisation study using data from UK Biobank.

Yuan Yuan, Yong Jiang, Chonghui Hu, Daixin Wu, Huimou Chen, Qing Tian, Rihua He, Tingting Li, Tianhao Huang, Honghui Jiang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yuan Yuan *Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.ORCID http://orcid.org/0000-0003-4809-8759
Yong Jiang *Pancreas Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
Chonghui Hu *Pancreas Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
Daixin WuFirst School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.
Huimou ChenOncology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Qing TianSchool of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
Rihua HePancreas Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
Tingting LiSchool of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
Tianhao HuangPancreas Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
Honghui JiangPancreas Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
Wentao ZhongGuangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
Yuan ChenSchool of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, China.
Jiale JiangThe First Clinical College, Changsha Medical University, Changsha, Hunan, China.
Shangyou ZhengPancreas Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China chenrufu@gdph.org.cn zhengshangyou@gdph.org.cn.
Rufu ChenGuangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China chenrufu@gdph.org.cn zhengshangyou@gdph.org.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveLiver diseases are established risk factors for hepatobiliary and pancreatic cancers. This study explores the relationship between liver disease and hepatobiliary-pancreatic cancers, focusing on transaminase levels and genetic susceptibility.

methodsWe conducted a large cohort study using data from 449 815 participants in the UK Biobank. Logistic regression models assessed cancer risks in liver disease versus control groups. The association between transaminase levels, polygenic risk scores (PRS), and hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), biliary tract cancer, and pancreatic cancer was examined. Two-sample Mendelian randomisation (MR) investigated the causal relationships between liver diseases and the four cancers.

resultsLiver disease and elevated transaminase levels were significantly associated with increased cancer risks (p<0.001). Higher alanine transaminase and aspartate transaminase PRS were linked to increased HCC risk (HR=1.69, 95% CI 1.38 to 2.08; HR=1.79, 95% CI 1.46 to 2.19). MR analysis revealed a causal link between alcohol-associated liver disease (ALD) and both HCC (OR=1.379, 95% CI 1.109 to 1.714) and ICC (OR=1.429, 95% CI 1.130 to 1.807), while metabolic dysfunction-associated steatotic liver disease showed no significant associations.

conclusionPatients with liver diseases have a significantly higher risk of hepatobiliary and pancreatic cancers, and individuals with elevated transaminase levels also exhibit a genetic predisposition to HCC. ALD demonstrates significant causal relationships with HCC and ICC.

Indexed as

Bile Duct NeoplasmsBiliary Tract NeoplasmsCarcinoma, HepatocellularCholangiocarcinomaLiver DiseasesLiver NeoplasmsPancreatic NeoplasmsAgedAlanine TransaminaseAspartate AminotransferasesBiological Specimen BanksCohort StudiesFemaleGenetic Predisposition to DiseaseHumansMaleAlanine TransaminaseAspartate AminotransferasesALCOHOLIC LIVER DISEASECANCERCHRONIC LIVER DISEASE

Identifiers

PMID40645641
PMCPMC12248208

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.